Cervical Lymph Node Involvement above the Supraclavicular Fossa in Breast Cancer: Comparison with Stage IIIC (KROG 18-02)
| Autor: | Jee Suk Chang, Tae Hyun Kim, Jin Ho Kim, Jinhee Kim, Doo Ho Choi, Su Ssan Kim, Seung Do Ahn, Jihye Cha, Hae Jin Park, Sun Young Lee, Mison Chun, Kyubo Kim, Dong Soo Lee, Kyung Hwan Shin, Yong Bae Kim, Won Park, Jae Sik Kim |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Survival Breast surgery medicine.medical_treatment Neoplasm metastasis Metastasis 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine medicine Stage IIIC Breast Lymph node business.industry Carcinoma Neck dissection medicine.disease Supraclavicular lymph nodes 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Neoplasm staging Original Article Supraclavicular fossa business |
| Zdroj: | Journal of Breast Cancer |
| ISSN: | 2092-9900 1738-6756 |
| Popis: | Purpose We aimed to analyze the treatment outcomes of ipsilateral cervical lymph node (CLN)-positive breast cancer without other distant metastasis and compare the outcomes with those of supraclavicular lymph node (SCL)-positive breast cancer. Methods Seventy-eight patients with breast cancer and ipsilateral CLN metastasis above the supraclavicular fossa (CLN[+] group) were treated at 7 institutions (2000-2014). Seventy-four patients received systemic chemotherapy and breast surgery followed by locoregional radiotherapy. Outcomes of the CLN(+) group were compared with those of the SCL(+) group, which included 183 patients with SCL involvement. Results The median follow-up duration was 55.9 months. Twenty-two regional failures were found in 15 patients-axillary lymph node (LN) in 8, SCL in 6, internal mammary LN in 3, previously involved CLN in 4, and previously uninvolved ipsilateral CLN in one patient. The 5-year overall survival (OS), disease-free survival (DFS), locoregional relapse-free survival (LRRFS), and distant metastasis-free survival (DMFS) rates were 68.6%, 46.7%, 68.4%, and 57.0%, respectively. Neck dissection did not improve LRRFS and DFS (p = 0.86 and p = 0.26, respectively). Multivariate analysis showed that hormone receptor negativity and the presence of extracapsular extension were prognostic factors for poor DFS. On comparison with stage IIIC using propensity score matching, survival outcomes of the CLN(+) and SCL(+) groups were not different (5-year OS, p = 0.75; DFS, p = 0.88; LRRFS, p = 0.86; and DMFS, p = 0.45). Conclusion The comparable clinical outcomes indicate that patients with breast cancer who have ipsilateral CLN metastasis without other distant metastasis may benefit from locoregional treatment of the ipsilateral breast and systemic therapies, as do those with N3c disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|